Halia Therapeutics, Inc. Clinical Trial Pipeline: 3 Active Trials, 4 Changes This Month

3

Active Trials

1

Recruiting

2

Disease Areas

4

Changes, 30 Days

What Changed in the Last 30 Days

Detected	Trial	Change
2026-08-06	NCT07399171 Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in…	Recruitment opened
2026-08-06	NCT07399171 Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in…	date change Primary completion pushed: 2027-05-20 -> 2028-02
2026-08-06	NCT07399171 Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in…	date change Completion pushed: 2027-08-20 -> 2028-07
2026-08-05	NCT07052006 A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk…	date change Completion pushed: 2026-05-25 -> 2026-08-14

New Trial Filings, Last 30 Days

First Posted	Trial	Phase	Status
2026-07-31	NCT07738510 Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic…	Phase 2	Not Yet Recruiting

Active Trials by Phase

Phase 2

3

Active Trials

NCT ID	Title	Condition	Status
Phase 2
NCT07399171	Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in…	Alzheimers Disease	Recruiting
NCT07738510	Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic…	Myelodysplastic Syndromes	Not Yet Recruiting
NCT07052006	A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk…	Myelodysplastic Syndrome	Active, Not Recruiting

Disease Areas

Get alerts when Halia Therapeutics, Inc.'s trials change

Status changes, date slips, and new filings — detected daily, delivered to your inbox.